View Older Stories View More Recent Stories

Nov 3, 2022 08:00AM Exelixis and Catalent Enter into New License Agreement for Three Antibody-Drug Conjugate Programs with the Potential to Accelerate Exelixis’ Biologics Pipeline
Nov 1, 2022 04:08PM Exelixis (EXEL) and Sairopa Establish Exclusive Clinical Development Collaboration and Option Agreement to Develop ADU-1805
Nov 1, 2022 04:07PM Exelixis (EXEL) and Cybrexa Therapeutics Establish Exclusive Collaboration Providing Exelixis the Right to Acquire CBX-12
Nov 1, 2022 04:07PM Exelixis and Sairopa Establish Exclusive Clinical Development Collaboration and Option Agreement to Develop ADU-1805, a Potentially Best-in-Class Monoclonal Antibody Targeting SIRPα
Nov 1, 2022 04:06PM Exelixis and Cybrexa Therapeutics Establish Exclusive Collaboration Providing Exelixis the Right to Acquire CBX-12, a Potential First-in-Class Peptide-Drug Conjugate of Exatecan
Nov 1, 2022 04:05PM Exelixis Announces Third Quarter 2022 Financial Results and Provides Corporate Update
Oct 26, 2022 05:49AM Exelixis (EXEL) Reports Promising Initial Dose-Escalation Results from Phase 1 JEWEL-101 Trial of XB002
Oct 26, 2022 04:00AM Exelixis Announces Promising Initial Dose-Escalation Results from the First-in-Human Phase 1 JEWEL-101 Trial Evaluating XB002 in Patients with Advanced Solid Tumors at ENA 2022
Oct 18, 2022 04:05PM Exelixis to Release Third Quarter 2022 Financial Results on Tuesday, November 1, 2022
Oct 4, 2022 08:03AM Exelixis (EXEL) Expands Clinical Trial Collaboration and Supply Agreement with Bristol Myers Squibb (BMY)
Oct 4, 2022 08:00AM Exelixis Expands Clinical Trial Collaboration and Supply Agreement with Bristol Myers Squibb to Include the Fixed-Dose Combination of Nivolumab and Relatlimab in Combination with XL092 in Phase 1b STE
Sep 10, 2022 03:00AM Exelixis Announces Dose-Escalation Results from the Phase 1 STELLAR-001 Trial Evaluating XL092 Alone and in Combination with an Immune Checkpoint Inhibitor in Patients with Advanced Solid Tumors at ES
Sep 8, 2022 06:22AM Exelixis (EXEL) Announces More Detailed Results of Phase 3 COSMIC-313 Trial in Advanced Kidney Cancer at ESMO
Sep 7, 2022 06:05PM Exelixis Announces Detailed Results from Phase 3 COSMIC-313 Pivotal Trial in Patients with Previously Untreated Advanced Kidney Cancer at ESMO 2022
Sep 6, 2022 04:05PM Exelixis To Webcast Fireside Chats as Part of Investor Conferences in September
Aug 9, 2022 04:05PM Exelixis Announces Second Quarter 2022 Financial Results and Provides Corporate Update
Jul 26, 2022 04:05PM Exelixis to Release Second Quarter 2022 Financial Results on Tuesday, August 9, 2022
Jul 11, 2022 08:01AM Exelixis (EXEL) Announces Cabozantinib in Combination with Nivolumab and Ipilimumab Significantly Improved PFS in Phase 3 COSMIC-313 Pivotal Trial in Patients with Previously Untreated Advanced Kidney
Jul 11, 2022 08:00AM Exelixis Announces Cabozantinib in Combination with Nivolumab and Ipilimumab Significantly Improved Progression-Free Survival in Phase 3 COSMIC-313 Pivotal Trial in Patients with Previously Untreated
Jul 7, 2022 12:00AM Exelixis and Ryvu Therapeutics Establish Exclusive License Agreement to Develop Novel STING Agonist-Based Targeted Cancer Therapies
Jul 5, 2022 04:05PM Exelixis to Webcast Fireside Chat as Part of the William Blair Biotech Focus Conference
Jun 21, 2022 08:00AM Exelixis Announces Initiation of the STELLAR-303 Phase 3 Pivotal Trial Evaluating XL092 in Patients with Metastatic Colorectal Cancer
Jun 16, 2022 12:00AM Exelixis and BioInvent Establish Exclusive Option and License Agreement to Develop Novel Antibody-Based Immuno-Oncology Therapies
May 31, 2022 04:05PM Exelixis To Webcast Fireside Chats as Part of Investor Conferences in June
May 26, 2022 05:00PM Exelixis (EXEL) Reports Results from Phase 2 Trial of Cabozantinib in Combination with Pembrolizumab
May 26, 2022 05:00PM Exelixis Announces Results from Phase 2 Trial of Cabozantinib in Combination with Pembrolizumab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma at ASCO 2022
May 26, 2022 05:00PM Exelixis Announces Detailed Results from Urothelial Carcinoma and Non-Small Cell Lung Cancer Cohorts of the COSMIC-021 Trial at ASCO 2022
May 10, 2022 04:05PM Exelixis Announces First Quarter 2022 Financial Results and Provides Corporate Update
May 4, 2022 04:05PM Exelixis To Webcast Fireside Chats as Part of Investor Conferences in May
May 3, 2022 08:00AM Exelixis’ Partner Ipsen Receives European Commission Approval for CABOMETYX® (cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer
Apr 26, 2022 04:05PM Exelixis to Release First Quarter 2022 Financial Results on Tuesday, May 10, 2022
Apr 26, 2022 08:03AM Phathom Pharmaceuticals (PHAT) Appoints Frank Karbe to its Board of Directors
Apr 26, 2022 08:00AM Phathom Pharmaceuticals Appoints Frank Karbe to its Board of Directors
Apr 26, 2022 08:00AM Phathom Pharmaceuticals Appoints Frank Karbe to its Board of Directors
Apr 14, 2022 08:00AM Exelixis Announces Initiation of First-In-Human Phase 1 Trial Evaluating XL114 Monotherapy in Patients with Non-Hodgkin’s Lymphoma
Apr 13, 2022 04:06PM Exelixis (EXEL) Announces Charles Cohen, Ph.D., to Retire from Board of Directors
Apr 13, 2022 04:05PM Exelixis Announces Charles Cohen, Ph.D., to Retire from Board of Directors
Mar 25, 2022 08:49AM Exelixis (EXEL) Partner Ipsen Receives Positive CHMP Opinion for CABOMETYX for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer
Mar 25, 2022 08:49AM Exelixis’ Partner Ipsen Receives Positive CHMP Opinion for CABOMETYX® (cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer
Mar 14, 2022 04:11PM Exelixis (EXEL) Announces Final OS Results from Phase 3 COSMIC-312 Trial of Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Patients with Previously Untreated Advanced Liver Cancer
Mar 14, 2022 04:05PM Exelixis Announces Final Overall Survival Results from Phase 3 COSMIC-312 Trial of Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Patients with Previously Untreated Advanced Liver
Mar 2, 2022 04:05PM Exelixis To Webcast Fireside Chats as Part of Investor Conferences in March
Feb 17, 2022 04:05PM Exelixis Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
Feb 14, 2022 05:02PM Bristol-Myers Squibb (BMY) and Exelisis (EXEL) Report that Opdivo in Combination with CABOMETYX Demonstrates Continued Survival Benefits with Over Two Years of Follow-Up in the CheckMate -9ER Trial
Feb 14, 2022 05:00PM Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Demonstrates Continued Survival Benefits with Over Two Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal C
Feb 3, 2022 04:05PM Exelixis to Release Fourth Quarter and Full Year 2021 Financial Results on Thursday, February 17, 2022
Jan 18, 2022 05:31PM Exelixis (EXEL) Reports Detailed Results for Cabozantinib in Combination with Immunotherapies
Jan 18, 2022 05:30PM Exelixis Announces Detailed Results for Cabozantinib in Combination with Immunotherapies in Patients with Advanced Colorectal Cancer at ASCO GI 2022
Jan 10, 2022 05:48AM Exelixis (EXEL) Reports Prelim Q4 Results; Issues 2022 Guidance and Key Milestones
Jan 9, 2022 04:00PM Exelixis Announces Preliminary Fourth Quarter and Full Year 2021 Financial Results, Provides 2022 Financial Guidance, and Outlines Key Priorities and Milestones for 2022
View More Recent Stories View Older Stories